Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Clevudine in Chronic Hepatitis B
NCT00558818Phase 4Completed
- Sponsor
- Bukwang Pharmaceutical
- Start
- Jun 2007
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of clevudine in Chronic Hepatitis B (CHB), sponsored by Bukwang Pharmaceutical. Primary endpoint: Proportion of patients with HBV DNA below the assay limit of detection at 96 weeks. Started Jun 2007; status: completed.
02
Drugs
clevudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00558818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00558818.